This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
ERCC1 Monoclonal Antibody (8F1)
catalog :
MA5-13912
quantity :
500 µL
price :
US 446.00
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
8F1
reactivity :
human, mouse, rat
application :
western blot, immunohistochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section
citations: 70
Reference
Kulkarni S, Solomon M, Pankaj D, Carnelio S, Chandrashekar C, Shetty N. Elucidating the role of excision repair cross-complement group 1 in oral epithelial dysplasia and early invasive squamous cell carcinoma: An immunohistochemical study. J Oral Maxillofac Pathol. 2020;24:20-25 pubmed publisher
Koussounadis A, Langdon S, Um I, Kay C, Francis K, Harrison D, et al. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer. 2016;16:205 pubmed publisher
Kato R, Hasegawa K, Torii Y, Udagawa Y, Fukasawa I. Factors affecting platinum sensitivity in cervical cancer. Oncol Lett. 2015;10:3591-3598 pubmed
Tian Y, Paramasivam M, Ghosal G, Chen D, Shen X, Huang Y, et al. UHRF1 contributes to DNA damage repair as a lesion recognition factor and nuclease scaffold. Cell Rep. 2015;10:1957-66 pubmed publisher
Muley T, Sianidou M, Thomas M, Bischoff H, Dienemann H, Meister M, et al. Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer. Anticancer Res. 2014;34:3707-13 pubmed
Steffensen K, Smoter M, Waldstrøm M, Grala B, Bodnar L, Stec R, et al. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression. Int J Oncol. 2014;44:1736-44 pubmed publisher
Han J, Baek S, Lee J, Kim G, Kim S, Lee S. Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil. Cancer Res Treat. 2014;46:55-64 pubmed publisher
Cubillo A, Rodriguez Pascual J, Lopez Rios F, Plaza C, Garcia E, Alvarez R, et al. Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer. Am J Clin Oncol. 2016;39:236-42 pubmed publisher
Kalogeraki A, Karvela Kalogeraki I, Tamiolakis D, Petraki P, Saridaki Z, Tzardi M. ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samples. Rev Port Pneumol. 2014;20:200-7 pubmed publisher
Mehra R, Zhu F, Yang D, Cai K, Weaver J, Singh M, et al. Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. Clin Cancer Res. 2013;19:6633-43 pubmed publisher
Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, et al. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. Lung Cancer. 2013;82:324-9 pubmed publisher
Yamashita F, Azuma K, Yoshida T, Yamada K, Kawahara A, Hattori S, et al. Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy. PLoS ONE. 2013;8:e71356 pubmed publisher
Mendoza J, Martinez J, Hernandez C, Perez Montiel D, Castro C, Fabián Morales E, et al. Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours. Br J Cancer. 2013;109:68-75 pubmed publisher
Yan D, Wei P, An G, Chen W. Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer. J Cardiothorac Surg. 2013;8:149 pubmed publisher
Gerhard R, Carvalho A, Carneiro V, Bento R, Uemura G, Gomes M, et al. Clinicopathological significance of ERCC1 expression in breast cancer. Pathol Res Pract. 2013;209:331-6 pubmed publisher
Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, et al. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer. 2013;108:1695-703 pubmed publisher
Friboulet L, Olaussen K, Pignon J, Shepherd F, Tsao M, Graziano S, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013;368:1101-10 pubmed publisher
Cubillo A, Hernando Requejo O, Garcia Garcia E, Rodriguez Pascual J, de Vicente E, Morelli P, et al. A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer. Am J Clin Oncol. 2014;37:117-21 pubmed publisher
Kao S, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, et al. Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma. Clin Lung Cancer. 2013;14:164-71 pubmed publisher
Thariat J, Bensadoun R, Etienne Grimaldi M, Grall D, Penault Llorca F, Dassonville O, et al. Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02). Clin Cancer Res. 2012;18:5123-33 pubmed
Monica V, Longo M, Felice B, Scagliotti G, Papotti M, Novello S. Role of hormone receptor expression in patients with advanced-stage lung cancer treated with chemotherapy. Clin Lung Cancer. 2012;13:416-23 pubmed publisher
Huang P, Li Y, Mai H, Luo R, Cai Y, Zhang L. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. Oral Oncol. 2012;48:964-968 pubmed publisher
Facista A, Nguyen H, Lewis C, Prasad A, Ramsey L, Zaitlin B, et al. Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer. Genome Integr. 2012;3:3 pubmed publisher
Planchard D, Camara Clayette V, Dorvault N, Soria J, Fouret P. p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients. Cancer. 2012;118:5015-25 pubmed publisher
Hao D, Lau H, Eliasziw M, Box A, Diaz R, Klimowicz A, et al. Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status. Head Neck. 2012;34:785-91 pubmed publisher
Zimling Z, Sørensen J, Gerds T, Bech C, Andersen C, Santoni Rugiu E. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol. 2012;7:249-56 pubmed publisher
Hasegawa K, Kato R, Torii Y, Ichikawa R, Oe S, Udagawa Y. The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma. Int J Gynecol Cancer. 2011;21:1479-85 pubmed publisher
Rodrigo R, Nathalie A, Elodie T, Gonzalo G, Philippe T, Françoise D, et al. Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas. Eur J Cancer. 2011;47:1319-27 pubmed publisher
Gadgeel S, Ruckdeschel J, Patel B, Wozniak A, Konski A, Valdivieso M, et al. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer. J Thorac Oncol. 2011;6:927-33 pubmed publisher
Maithel S, Coban I, Kneuertz P, Kooby D, El Rayes B, Kauh J, et al. Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection. Ann Surg Oncol. 2011;18:2699-705 pubmed publisher
Stoepker C, Hain K, Schuster B, Hilhorst Hofstee Y, Rooimans M, Steltenpool J, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet. 2011;43:138-41 pubmed publisher
Kim Y, Lach F, Desetty R, Hanenberg H, Auerbach A, Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet. 2011;43:142-6 pubmed publisher
Kim K, Kwon H, Oh S, Kim S, Lee S, Kwon K, et al. Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers. 2011;16:74-82 pubmed publisher
Mancuso A, Sacchetta S, Saletti P, Tronconi C, Milesi L, Garassino M, et al. Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey. Anticancer Res. 2010;30:4289-95 pubmed
Doll C, Prystajecky M, Eliasziw M, Klimowicz A, Petrillo S, Craighead P, et al. Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiother Oncol. 2010;97:352-9 pubmed publisher
Scheil Bertram S, Tylus Schaaf P, du Bois A, Harter P, Oppitz M, Ewald Riegler N, et al. Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma. Gynecol Oncol. 2010;119:325-31 pubmed publisher
Lee S, Park Y, Kim K, Cho E, Ahn Y, Kim K, et al. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell c. Br J Cancer. 2010;103:845-51 pubmed publisher
Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli J, et al. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer. 2010;17:797-807 pubmed publisher
Jeong S, Han J, Kim J, Ahn M, Hwang Y, Lee H, et al. Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. Dig Dis Sci. 2011;56:131-8 pubmed publisher
Vilmar A, Santoni Rugiu E, Sørensen J. ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer. 2010;46:1554-62 pubmed publisher
Vilmar A, Santoni Rugiu E, Sørensen J. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol. 2010;21:1817-24 pubmed publisher
Righi L, Papotti M, Ceppi P, Billè A, Bacillo E, Molinaro L, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol. 2010;28:1534-9 pubmed publisher
Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G, et al. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol. 2010;65:1009-21 pubmed publisher
Skov B, Holm B, Erreboe A, Skov T, Mellemgaard A. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol. 2010;5:453-9 pubmed publisher
Shao Y, Kuo K, Hu F, Lu Y, Huang C, Liau J, et al. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Jpn J Clin Oncol. 2010;40:286-93 pubmed publisher
Fountzilas G, Kalogera Fountzila A, Lambaki S, Wirtz R, Nikolaou A, Karayannopoulou G, et al. MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. J Oncol. 2009;2009:305908 pubmed publisher
Gomez Roca C, Raynaud C, Penault Llorca F, Mercier O, Commo F, Morat L, et al. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol. 2009;4:1212-20 pubmed publisher
Holm B, Mellemgaard A, Skov T, Skov B. Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol. 2009;27:4254-9 pubmed publisher
Steffensen K, Waldstrøm M, Jakobsen A. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19:820-5 pubmed publisher
Jeong S, Jung J, Han J, Kim J, Choi Y, Lee H, et al. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. Lung Cancer. 2010;68:288-94 pubmed publisher
Wang X, Zhao J, Yang L, Mao L, An T, Bai H, et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol. 2010;27:484-90 pubmed publisher
Planchard D, Domont J, Taranchon E, Monnet I, Tredaniel J, Caliandro R, et al. The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. Ann Oncol. 2009;20:1257-63 pubmed publisher
Ronchi C, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, et al. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer. 2009;16:907-18 pubmed publisher
Lee H, Choi Y, Han J, Kim J, Jung J, Jeong S, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer. 2009;65:377-82 pubmed publisher
Han S, Oh D, Im S, Park S, Lee K, Song H, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer. 2009;100:298-304 pubmed publisher
Kim Y, Ishii G, Goto K, Ota S, Kubota K, Murata Y, et al. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer. 2009;65:105-11 pubmed publisher
Wu Y, Mitchell T, Zhu X. Human XPF controls TRF2 and telomere length maintenance through distinctive mechanisms. Mech Ageing Dev. 2008;129:602-10 pubmed publisher
Kim M, Cho K, Kwon G, Park S, Kim Y, Kim J, et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res. 2008;14:4225-31 pubmed publisher
Rubio D, Garcia S, Paz M, de la Cueva T, Lopez Fernandez L, Lloyd A, et al. Molecular characterization of spontaneous mesenchymal stem cell transformation. PLoS ONE. 2008;3:e1398 pubmed publisher
Sidoni A, Cartaginese F, Colozza M, Gori S, Crino L. ERCC1 expression in triple negative breast carcinoma: the paradox revisited. Breast Cancer Res Treat. 2008;111:569-70 pubmed
Kim M, Cho K, Kwon G, Park S, Kim Y, Kim J, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer. 2008;44:54-60 pubmed
Al Minawi A, Saleh Gohari N, Helleday T. The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Res. 2008;36:1-9 pubmed
Fujii T, Toyooka S, Ichimura K, Fujiwara Y, Hotta K, Soh J, et al. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer. 2008;59:377-84 pubmed
Lee H, Han J, Kim J, Lee M, Jeong S, Kang S, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer. 2008;59:95-104 pubmed
Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci. 2007;98:1336-43 pubmed
Handra Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau St Guily J, Soria J, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carci. Clin Cancer Res. 2007;13:3855-9 pubmed
Taillade L, Penault Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, et al. Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol. 2007;18:1043-50 pubmed
Wu Y, Zacal N, Rainbow A, Zhu X. XPF with mutations in its conserved nuclease domain is defective in DNA repair but functions in TRF2-mediated telomere shortening. DNA Repair (Amst). 2007;6:157-66 pubmed
Olaussen K, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-91 pubmed
Wachters F, Wong L, Timens W, Kampinga H, Groen H. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer. 2005;50:211-9 pubmed
product information
Product Type :
Antibody
Product Name :
ERCC1 Monoclonal Antibody (8F1)
Catalog # :
MA5-13912
Quantity :
500 µL
Price :
US 446.00
Clonality :
Monoclonal
Purity :
protein A
Host :
Mouse
Reactivity :
Human, Mouse, Rat
Applications :
Flow Cytometry: 0.5-1 µg/test, Immunohistochemistry (Paraffin): 1:100-1:500, Immunoprecipitation: Assay-dependent, Western Blot: Assay-dependent
Species :
Human, Mouse, Rat
Clone :
8F1
Isotype :
IgG2b
Storage :
4° C
Description :
ERCC1 is a non-catalytic component of a structure-specific DNA repair endonuclease responsible for the 5'-incision during DNA repair. It is responsible, in conjunction with SLX4, for the first step in the repair of interstrand cross-links (ICL). It participates in the processing of anaphase bridge-generating DNA structures, which consist in incompletely processed DNA lesions arising during S or G2 phase, and can result in cytokinesis failure. ERCC1 is also required for homology-directed repair (HDR) of DNA double-strand breaks, in conjunction with SLX4. (Uniprot)
Immunogen :
Recombinant full length human ERCC1 protein
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: 0.5-1 µg/test, Immunohistochemistry (Paraffin): 1:100-1:500, Immunoprecipitation: Assay-dependent, Western Blot: Assay-dependent
Aliases :
COFS4; DNA excision repair protein ERCC-1; ERCC excision repair 1, endonuclease non-catalytic subunit; Ercc1; Ercc-1; excision repair cross-complementation group 1; excision repair cross-complementing 1; excision repair cross-complementing rodent repair deficiency, complementation group 1; excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence); hypothetical protein LOC405807; RAD10; UV20; zgc:77511
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA